Takigawa et al identified prognostic factors associated with survival in patients with advanced non-small cell lung cancer (NSCLC). This can help identify patients who may benefit from aggressive or more novel therapies. The authors are from National Shikoku Cancer Center Hospital in Matsuyama, Japan.
Patient selection:
(1) non-small cell lung cancer
(2) advanced disease
(3) ECOG performance scale 0 to 3
Non-small cell lung cancer includes:
(1) squamous cell carcinoma
(2) adenocarcinoma
(3) large cell undifferentiated carcinoma
Advanced disease includes locally advanced disease (Stage III) and metastatic disease (Stage IV).
Parameters identified by multivariate analysis:
(1) ECOG performance scale (PS)
(2) Stage
(3) hemoglobin
(4) unintended weight loss
|
ECOG PS |
Stage |
Hemoglobin |
Weight Loss |
Group |
|
0 or 1 |
III |
> 11 g/dL |
NA |
I |
|
0 or 1 |
III |
<= 11 g/dL |
NA |
II |
|
0 or 1 |
IV |
NA |
NA |
II |
|
2 or 3 |
NA |
NA |
< 5% |
II |
|
2 or 3 |
NA |
NA |
>= 5% |
III |
|
Group |
Median Survival |
Percent 1 Year Survival |
Percent 2 Year Survival |
|
I |
95 weeks |
68% |
46% |
|
II |
39 weeks |
38% |
13% |
|
III |
17 weeks |
4% |
0% |
Specialty: Hematology Oncology, Surgery, general, Pulmonology
ICD-10: ,
